Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.2
4.8
Journals
Nutrients
Special Issues
Endocrinology and Metabolic Diseases in Human Health
nutrients-logo
Submit to Nutrients Review for Nutrients Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Endocrinology and Metabolic Diseases in Human Health

A special issue of Nutrients (ISSN 2072-6643). This special issue belongs to the section "Nutrition and Metabolism".

Deadline for manuscript submissions: closed (15 December 2022) | Viewed by 24766

Special Issue Editors

Prof. Dr. Elena Grasselli

E-Mail Website
Guest Editor
DISTAV, Dipartimento di Scienze della Terra, dell'Ambiente e della Vita, Università di Genova, Genova, Italy
Interests: endocrine disruptors; obesogens; hormones; lipid Metabolism
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Ilaria Demori

E-Mail Website
Guest Editor
DISTAV, Dipartimento di Scienze della Terra, dell'Ambiente e della Vita, Università di Genova, Genova, Italy
Interests: nutrition and metabolism; nutrition and stress; physiology of stress; Psychoneuroendocrineimmunology (PNEI)
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Metabolic non-communicable diseases represent a major threat for human health in Western- lifestyle countries. Hormonal unbalances play a role in the pathogenesis of severe conditions such as obesity, diabetes, dyslipidemia, and metabolic syndrome. Dysfunctions affecting the main endocrine glands (pituitary, thyroid, adrenals, pancreas, etc.) have detrimental effects on metabolic regulation.

Food intake and diet composition are the main signals for the production and secretion of gastrointestinal and pancreatic hormones that allow the proper digestion, absorption and metabolism of nutrients, thus regulating energy homeostasis. The gut microbiota represents a huge source of signaling molecules able to crosstalk with hormones from the host. Moreover, micronutrients such as vitamins and minerals are necessary for the proper function of the endocrine system. Finally, the recent obesogen hypothesis has underlined how endocrine disruptors found in food products can negatively influence lipid homeostasis, thus contributing to metabolic disease.

In this scenario, the bidirectional communication between nutrition and endocrinology can be regarded as a causal network at the basis of human health. From this point of view, dietary interventions are needed within the framework of integrated preventive and therapeutic strategies against endocrine and metabolic diseases.

In this Special Issue, we welcome high-quality research papers, observational and clinical trials, and narrative and systematic reviews in the field of endocrinology, metabolism, diet, and human health.

Prof. Dr. Elena Grasselli
Prof. Dr. Ilaria Demori
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nutrients is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetes
  • obesity
  • antioxidants
  • non-alcoholic fatty liver disease (NAFLD)
  • stress hormones
  • thyroid hormones
  • insulin resistance
  • dyslipidemia
  • macronutrients
  • micronutrients
  • mediterranean diet
  • ketogenic diet
  • carbohydrates
  • proteins
  • lipids
  • metabolic syndrome
  • endocrine dysfunctions
  • endocrine disruptors
  • obesogens
  • gut microbiota

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

14 pages, 5224 KiB  
Article
Effects of Initial Combinations of Gemigliptin Plus Metformin Compared with Glimepiride Plus Metformin on Gut Microbiota and Glucose Regulation in Obese Patients with Type 2 Diabetes: The INTESTINE Study
by Soo Lim, Minji Sohn, Jose C. Florez, Michael A. Nauck and Jiyoung Ahn
Nutrients 2023, 15(1), 248; https://doi.org/10.3390/nu15010248 - 3 Jan 2023
Cited by 5 | Viewed by 5667
Abstract
The efficacy and safety of medications can be affected by alterations in gut microbiota in human beings. Among antidiabetic medications, incretin-based therapy such as dipeptidyl peptidase 4 inhibitors might affect gut microbiomes, which are related to glucose metabolism. This was a randomized, controlled, [...] Read more.
The efficacy and safety of medications can be affected by alterations in gut microbiota in human beings. Among antidiabetic medications, incretin-based therapy such as dipeptidyl peptidase 4 inhibitors might affect gut microbiomes, which are related to glucose metabolism. This was a randomized, controlled, active-competitor study that aimed to compare the effects of combinations of gemigliptin–metformin vs. glimepiride–metformin as initial therapies on gut microbiota and glucose homeostasis in drug-naïve patients with type 2 diabetes. Seventy drug-naïve patients with type 2 diabetes (mean age, 52.2 years) with a glycated hemoglobin (HbA1c) level ≥7.5% were assigned to either gemigliptin–metformin or glimepiride–metformin combination therapies for 24 weeks. Changes in gut microbiota, biomarkers linked to glucose regulation, body composition, and amino acid blood levels were investigated. Although both treatments decreased the HbA1c levels significantly, the gemigliptin–metformin group achieved HbA1c ≤ 7.0% without hypoglycemia or weight gain more effectively than did the glimepiride–metformin group (59% vs. 24%; p < 0.05). At the phylum level, the Firmicutes/Bacteroidetes ratio tended to decrease after gemigliptin–metformin therapy (p = 0.065), with a notable depletion of taxa belonging to Firmicutes, including Lactobacillus, Ruminococcus torques, and Streptococcus (all p < 0.05). However, regardless of the treatment modality, a distinct difference in the overall gut microbiome composition was noted between patients who reached the HbA1c target goal and those who did not (p < 0.001). Treatment with gemigliptin–metformin resulted in a higher achievement of the glycemic target without hypoglycemia or weight gain, better than with glimepiride–metformin; these improvements might be related to beneficial changes in gut microbiota. Full article
(This article belongs to the Special Issue Endocrinology and Metabolic Diseases in Human Health)
►▼ Show Figures

Figure 1

10 pages, 686 KiB  
Article
Prevalence of Lactose Intolerance in Patients with Hashimoto Thyroiditis and Impact on LT4 Replacement Dose
by Elisa Marabotto, Diego Ferone, Afscin Djahandideh Sheijani, Lara Vera, Sebastiano Ziola, Edoardo Savarino, Giorgia Bodini, Manuele Furnari, Patrizia Zentilin, Vincenzo Savarino, Massimo Giusti, Fabiola Andrea Navarro Rojas, Marcello Bagnasco, Manuela Albertelli and Edoardo G. Giannini
Nutrients 2022, 14(15), 3017; https://doi.org/10.3390/nu14153017 - 22 Jul 2022
Cited by 2 | Viewed by 2892
Abstract
Purpose: to determine lactose intolerance (LI) prevalence in women with Hashimoto’s thyroiditis (HT) and assess the impact of LI on LT4 replacement dose. Methods. consecutive patients with HT underwent Lactose Breath Test and clinical/laboratory data collection. Unrelated gastrointestinal disorders were carefully ruled out. [...] Read more.
Purpose: to determine lactose intolerance (LI) prevalence in women with Hashimoto’s thyroiditis (HT) and assess the impact of LI on LT4 replacement dose. Methods. consecutive patients with HT underwent Lactose Breath Test and clinical/laboratory data collection. Unrelated gastrointestinal disorders were carefully ruled out. Lactose-free diet and shift to lactose-free LT4 were proposed to patients with LI. Results: we enrolled 58 females (age range, 23–72 years) with diagnosis of HT. In total, 15 patients were euthyroid without treatment, and 43 (74%) euthyroid under LT4 (30 of them with a LT4 formulation containing lactose). Gastrointestinal symptoms were present in 84.5% of patients, with a greater prevalence in change in bowel habits in lactose-intolerant patients (p < 0.0001). The cumulative LT4 dose required did not differ in patients with or without LI. No significant difference in both TSH values and LT4 dose were observed in patients shifted to lactose-free LT4 and diet at 3 and 6 months compared to baseline. Conclusion: the prevalence of LI in patients with HT was 58.6%, not different from global prevalence of LI. In the absence of other gastrointestinal disorders, LI seems not to be a major cause of LT4 malabsorption and does not affect the LT4 required dose in HT patients. Full article
(This article belongs to the Special Issue Endocrinology and Metabolic Diseases in Human Health)
►▼ Show Figures

Figure 1

14 pages, 714 KiB  
Article
Impact of Dietitian-Led Nutrition Therapy of Food Order on 5-Year Glycemic Control in Outpatients with Type 2 Diabetes at Primary Care Clinic: Retrospective Cohort Study
by Ayasa Nitta, Saeko Imai, Shizuo Kajiayama, Mikuko Matsuda, Takashi Miyawaki, Shinya Matsumoto, Shintaro Kajiyama, Yoshitaka Hashimoto, Neiko Ozasa and Michiaki Fukui
Nutrients 2022, 14(14), 2865; https://doi.org/10.3390/nu14142865 - 13 Jul 2022
Cited by 6 | Viewed by 5906
Abstract
The aim of this retrospective cohort study was to evaluate the effect of 5-year follow-up of dietitian-led medical nutrition therapy (eating vegetables before carbohydrates) on glycemic control in outpatients with type 2 diabetes (T2DM) at a primary care clinic. A total of 138 [...] Read more.
The aim of this retrospective cohort study was to evaluate the effect of 5-year follow-up of dietitian-led medical nutrition therapy (eating vegetables before carbohydrates) on glycemic control in outpatients with type 2 diabetes (T2DM) at a primary care clinic. A total of 138 patients with dietitian-led medical nutrition therapy (intervention group) and 104 patients without dietitian-led nutrition therapy (control group) were compared for glycemic control, serum lipid, blood pressure, and diabetic complications for 5 years. Each patient in the intervention group received dietary education focused on food order (eating vegetables before carbohydrates) by dietitians. A significant improvement in HbA1c after 5 years in the intervention group [8.5 ± 1.7% (69 mmol/mol) to 7.6 ± 1.1% (59 mmol/mol), p < 0.001] was observed, whereas no change was observed in the control group [7.9 ± 1.2% (62 mmol/mol) to 8.0 ± 1.2% (63 mmol/mol)]. Dietary intake of protein, fat, carbohydrates, cholesterol, and salt in the intervention group demonstrated significant reduction, while the intake of dietary fiber significantly increased after the dietary education. Simple dietary education of ‘eating vegetables before carbohydrates’ presented by dietitians achieved good glycemic control after a 5-year period in outpatients with T2DM at primary care clinic. Full article
(This article belongs to the Special Issue Endocrinology and Metabolic Diseases in Human Health)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

30 pages, 4143 KiB  
Review
Treatment of Dyslipidemia through Targeted Therapy of Gut Microbiota
by Brandon Flaig, Rachel Garza, Bhavdeep Singh, Sevag Hamamah and Mihai Covasa
Nutrients 2023, 15(1), 228; https://doi.org/10.3390/nu15010228 - 2 Jan 2023
Cited by 20 | Viewed by 5983
Abstract
Dyslipidemia is a multifaceted condition with various genetic and environmental factors contributing to its pathogenesis. Further, this condition represents an important risk factor for its related sequalae including cardiovascular diseases (CVD) such as coronary artery disease (CAD) and stroke. Emerging evidence has shown [...] Read more.
Dyslipidemia is a multifaceted condition with various genetic and environmental factors contributing to its pathogenesis. Further, this condition represents an important risk factor for its related sequalae including cardiovascular diseases (CVD) such as coronary artery disease (CAD) and stroke. Emerging evidence has shown that gut microbiota and their metabolites can worsen or protect against the development of dyslipidemia. Although there are currently numerous treatment modalities available including lifestyle modification and pharmacologic interventions, there has been promising research on dyslipidemia that involves the benefits of modulating gut microbiota in treating alterations in lipid metabolism. In this review, we examine the relationship between gut microbiota and dyslipidemia, the impact of gut microbiota metabolites on the development of dyslipidemia, and the current research on dietary interventions, prebiotics, probiotics, synbiotics and microbiota transplant as therapeutic modalities in prevention of cardiovascular disease. Overall, understanding the mechanisms by which gut microbiota and their metabolites affect dyslipidemia progression will help develop more precise therapeutic targets to optimize lipid metabolism. Full article
(This article belongs to the Special Issue Endocrinology and Metabolic Diseases in Human Health)
►▼ Show Figures

Figure 1

Other

Jump to: Research, Review

16 pages, 733 KiB  
Perspective
The Role of the Stress Response in Metabolic Dysfunction-Associated Fatty Liver Disease: A Psychoneuroendocrineimmunology-Based Perspective
by Ilaria Demori and Elena Grasselli
Nutrients 2023, 15(3), 795; https://doi.org/10.3390/nu15030795 - 3 Feb 2023
Cited by 4 | Viewed by 3155
Abstract
The novel term metabolic dysfunction-associated fatty liver disease (MAFLD), which has been proposed to describe the major cause of hepatic disease, pinpoints the coexistence of multiple metabolic disturbances and liver steatosis, giving rise to different phenotypic manifestations. Within the psychoneuroendocrineimmunological (PNEI) network that [...] Read more.
The novel term metabolic dysfunction-associated fatty liver disease (MAFLD), which has been proposed to describe the major cause of hepatic disease, pinpoints the coexistence of multiple metabolic disturbances and liver steatosis, giving rise to different phenotypic manifestations. Within the psychoneuroendocrineimmunological (PNEI) network that regulates body–mind interactions, the stress response plays a pervasive role by affecting metabolic, hormonal, immune, and behavioral balance. In this perspective, we focus on chronic psychosocial stress and high levels of cortisol to highlight their role in MAFLD pathogenesis and worsening. From a PNEI perspective, considering the stress response as a therapeutic target in MAFLD allows for simultaneously influencing multiple pathways in the development of MAFLD, including dysmetabolism, inflammation, feeding behaviors, gut–liver axis, and dysbiosis, with the hope of better outcomes. Full article
(This article belongs to the Special Issue Endocrinology and Metabolic Diseases in Human Health)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop